Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PLK1 inhibition enhances temozolomide efficacy in IDH1 mutant gliomas.

Oncotarget - 28 Feb 2017

Koncar Robert F, Chu Zhengtao, Romick-Rosendale Lindsey E, Wells Susanne I, Chan Timothy A, Qi Xiaoyang, Bahassi El Mustapha

Abstract excerpt

Despite multimodal therapy with radiation and the DNA alkylating agent temozolomide (TMZ), malignant gliomas remain incurable. Up to 90% of grades II-III gliomas contain a single mutant isocitrate dehydrogenase 1 (IDH1) allele. IDH1 mutant-mediated transformation is associated with TMZ resistance; however, there is no clinically available means of sensitizing IDH1 mutant tumors to TMZ. In this study we sought to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Cycle Proteins
Share to Dacarbazine
Share to Glioma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Isocitrate Dehydrogenase

Share to Polo-Like Kinase 1

Share to Protein Serine-Threonine Kinases

Share to Proto-Oncogene Proteins

Share to Temozolomide

Source

Open in PubMed Open full text

Identifiers

PMID: 28178660
DOI: 10.18632/oncotarget.15015
PMCID: PMC5362526

Genes

IDH1
PLK1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PLK1 inhibition enhances temozolomide efficacy in IDH1 mutant gliomas.PMID 28178660Read ↗

Mutant IDH1-driven cellular transformation increases RAD51-mediated homologous recombination and temozolomide resistance.Semantic proximity Read ↗

Targeting IDH-Mutant Glioma.Semantic proximity Read ↗

Novel IDH1-Targeted Glioma Therapies.Semantic proximity Read ↗

Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.Semantic proximity Read ↗

Inhibition of 2-Hydroxyglutrate Elicits Metabolic-reprograming and Mutant IDH1 Glioma ImmunitySemantic proximity Read ↗

Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in miceSemantic proximity Read ↗

IDH1 overexpression induced chemotherapy resistance and IDH1 mutation enhanced chemotherapy sensitivity in Glioma cells in vitro and in vivo.Semantic proximity Read ↗

Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair.Semantic proximity Read ↗

From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas.Semantic proximity Read ↗

A Brain Penetrant Mutant IDH1 Inhibitor Provides In Vivo Survival Benefit.Semantic proximity Read ↗

Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis.Semantic proximity Read ↗

IDH inhibition in gliomas: from preclinical models to clinical trialsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.